Yesterday Tris Pharma secured the FDA’s green light for Onyda XR, the first liquid non-stimulant nighttime treatment for attention deficit hyperactivity disorder in pediatric patients.
The company said it had begun a trial of its over-the-counter rapid test for detecting sexually transmitted infections (STI) such as chlamydia and gonorrhea, and aims to launch it by mid-2025.
The U.S. government is nearing an agreement to fund a late-stage trial of Moderna’s mRNA pandemic bird flu vaccine, the Financial Times reported on Thursday, as an H5N1 outbreak spreads through egg farms and among cattle herds.
As further sharp declines are expected for Humira, AbbVie has strategically pivoted to alternative immunology products to bolster its revenue streams. As such, two drugs, Skyrizi (risankizumab) and Rinvoq (upadacitinib), are emerging as key replacements. These products are forecast to collectively generate over $32 billion by 2030, enabling AbbVie to financially rebound and continue its position as a leading immunology player, says GlobalData.
Yesterday Amgen secured the FDA’s green light for the first interchangeable biosimilar to AstraZeneca’s Soliris to treat two rare diseases.
Laurie Hess, DVM, has joined the Merck Manuals team as Editor-in-Chief of the Merck Veterinary Manual and Director, Scientific Affairs.